Skip to main content
Premium Trial:

Request an Annual Quote

Gilead's Plan

Premium

Gilead Sciences wants to turn cancer into a condition that patients can manage with medication, even if they have to live with it for a long time, says CNN Money's Geoff Colvin. Colvin interviewed Gilead's CEO, John Martin, about his plans for Gilead and the company's plans to develop a new initiative to fight cancer. Gilead has just signed a new agreement with Yale to help identify molecular targets that could be inhibited in order to put cancer into remission, Martin says. "Just look at how, with HIV, we were able to come up with multiple products that we could use in combination to keep HIV basically in remission in a patient and let the patient live a normal life. With our chemistry and biological expertise, we envision doing a similar thing for cancer chemotherapy," he tells Colvin. Martin also says he wants to create medications that take into account real-world behavior of patients, and make it simple — not complicated — for patients to take their prescribed drugs.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.